Zelluna is developing TCR based cellular immunotherapy products for the treatment of solid tumors. Our current pipeline consists of allogeneic TCR-NK R&D programs targeting well validated antigens expressed across a broad range of solid tumors. Zelluna has integrated in-house TCR discovery and optimization capabilities and aims to advance the lead product to IND in 2025 with multiple preclinical projects following.
